Landaas & Co. WI ADV Trims Position in Abbott Laboratories $ABT

Landaas & Co. WI ADV trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 11.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,364 shares of the healthcare product maker’s stock after selling 434 shares during the quarter. Landaas & Co. WI ADV’s holdings in Abbott Laboratories were worth $458,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Intrust Bank NA raised its holdings in Abbott Laboratories by 5.3% in the 2nd quarter. Intrust Bank NA now owns 22,999 shares of the healthcare product maker’s stock worth $3,128,000 after purchasing an additional 1,153 shares during the period. Rothschild Investment LLC grew its holdings in Abbott Laboratories by 2.7% during the second quarter. Rothschild Investment LLC now owns 33,079 shares of the healthcare product maker’s stock valued at $4,499,000 after purchasing an additional 872 shares during the period. Pinnacle Financial Group LLC IL increased its position in Abbott Laboratories by 7.9% in the second quarter. Pinnacle Financial Group LLC IL now owns 1,756 shares of the healthcare product maker’s stock worth $239,000 after buying an additional 128 shares in the last quarter. Midwest Professional Planners LTD. raised its stake in shares of Abbott Laboratories by 50.0% in the second quarter. Midwest Professional Planners LTD. now owns 15,040 shares of the healthcare product maker’s stock worth $2,046,000 after buying an additional 5,010 shares during the period. Finally, Raiffeisen Bank International AG lifted its position in shares of Abbott Laboratories by 22.8% during the 2nd quarter. Raiffeisen Bank International AG now owns 327,419 shares of the healthcare product maker’s stock valued at $44,987,000 after buying an additional 60,735 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Benchmark initiated coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They set a “buy” rating and a $145.00 target price on the stock. Mizuho raised their price objective on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, October 14th. Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Daiwa Capital Markets upped their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Finally, The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Price Performance

ABT stock opened at $130.59 on Monday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The firm has a market capitalization of $227.08 billion, a P/E ratio of 16.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. The company has a fifty day simple moving average of $130.38 and a two-hundred day simple moving average of $131.36. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period in the prior year, the company earned $1.21 EPS. The business’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.